SmartDx launches AI canine DNA test for lifetime cancer and heart disease risk
SmartDx has introduced a direct-to-consumer canine DNA test that uses artificial intelligence and owner-provided information to estimate lifetime risks for cancer and heart disease. The company says the goal is to give dog owners and veterinarians more actionable information for preventive care decisions.
Why it matters: - SmartDx is trying to move dog DNA testing beyond breed identification and ancestry into disease-risk screening. - The platform is aimed at helping owners spot possible lifetime risks earlier, which could shape preventive care discussions with veterinarians. - The initial focus on cancer and heart disease targets two of the most serious health concerns for dogs.
What happened: - SmartDx introduced a direct-to-consumer canine health testing platform that uses a mouth swab to collect DNA. - The company says the test combines canine genetic information, owner-provided information and artificial intelligence to estimate lifetime risk for cancer and heart disease. - The announcement was made from Hawthorne, California, on Nov. 17, 2026.
The details: - SmartDx uses proprietary algorithms and machine-learning technology to look for patterns linked to disease susceptibility. - The platform includes two core tools: Morse, which converts raw genomic data into structured, model-ready data, and Mew, a machine-learning risk prediction engine. - Mew, short for Monte carlo Ensemble Wide, evaluates genetic information alongside relevant owner-provided information to generate disease-risk predictions. - Brent Keller, SmartDx co-founder, said the company wants to make sophisticated genomic and AI technology accessible to everyday dog owners and give them specific genetic mutation information they can discuss with veterinarians and consider in preventive-care decisions. - SmartDx says an “At Risk” result is not a diagnosis. - SmartDx also says a dog dying before disease symptoms appear does not count as a false positive. - When a dog is assessed as “At Risk,” the risk report includes related details to support interpretation. - SmartDx says the report is intended to complement veterinary examinations and professional medical advice, not replace them.
Between the lines: - SmartDx is positioning itself at the intersection of pet care, consumer genetics and AI-driven health forecasting. - The company is also signaling caution around how results should be used, which is important because predictive risk scores can be misunderstood as diagnoses. - The emphasis on veterinarian involvement suggests SmartDx wants the product to fit into existing medical decision-making, not bypass it.
What's next: - SmartDx says it aims to make canine genetic risk information more accessible. - The company expects that broader access to these risk reports will encourage a more informed and proactive approach to dog health. - The company’s website is More information.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Health Monitor Monaco
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.